Clinical Trials Logo

Melanoma In Situ clinical trials

View clinical trials related to Melanoma In Situ.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03233828 Terminated - Melanoma (Skin) Clinical Trials

Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2

IL-2
Start date: December 19, 2018
Phase: Phase 3
Study type: Interventional

This study is meant to assess the use of intralesional IL-2 to modulate the immunological response to suspected melanoma, or melanoma in situ, in an effort to increase lymphocyte infiltration and decrease disease metastasis. Patients that are clinically diagnosed with suspected Melanoma or Melanoma in situ will be assigned to either a treatment or control arm. The treatment group will be subjected to two intralesional IL-2 injections, whereas the control group will be subjected to two intralesional injections of saline. The proteomic and metabolomic profiles of both groups will be analyzed using urine and blood samples in an effort to assess the systemic immunological response, if any, to the treatment. Also, upon disease confirmation and staging by a qualified pathologist, lesions will be assessed for lymphocyte infiltration using immunohistochemical methods. This study will determine whether pre-treatment of IL-2 on lesions (clinically diagnosed as melanoma or melanoma in situ) is effective in generating an adaptive immune response, and whether that immune response may play a role in preventing disease metastasis.